泰德医药主要提供：1)合约研究机构(CRO)服务，即多肽新化学分子实体(NCE)发现合成;2)合约开发及生产机构(CDMO)服务，即多肽化学、制造及控制(CMC)开发;3)合约生产机构(CMO)服务，即多肽NCE及仿制造商业化生产。公司已建立全球业务，项目覆盖超过50个国家，其中包括中国、美国、日本、欧洲、韩国及澳大利亚等主要市场。公司为客户提供符合全球主要市场监管规定的多肽类药物开发、生产、CMC申报支持服务。According to the Hong Kong Stock Exchange disclosure on May 31, Ted Pharmaceuticals (Zhejiang) Co., Ltd. (hereinafter: Ted Pharmaceuticals) submitted a statement to the main board of the Hong Kong Stock Exchange. The co-sponsors are Morgan Stanley and CITIC Securities.
The Zhitong Finance App learned that according to the Hong Kong Stock Exchange disclosure on May 31, Ted Pharmaceuticals (Zhejiang) Co., Ltd. (hereinafter: Ted Pharmaceuticals) submitted a statement to the main board of the Hong Kong Stock Exchange. The co-sponsors are Morgan Stanley and CITIC Securities.
According to Frost & Sullivan, in terms of 2023 sales revenue, Ted Pharmaceuticals is the third largest contract research, development and production organization (CRDMO) in the world focusing on peptides. The company is also one of the most comprehensive CRDMOs in the world focusing on peptides, providing full-cycle services from early detection, pre-clinical research and clinical development to commercial production.
Ted Pharmaceuticals mainly provides: 1) contract research organization (CRO) services, that is, the discovery and synthesis of new peptide chemical molecular entities (NCE); 2) contract development and production organization (CDMO) services, that is, peptide chemistry, manufacturing and control (CMC) development; 3) contract manufacturing organization (CMO) services, that is, commercial production of peptides NCE and imitation manufacturing. The company has established a global business, with projects covering more than 50 countries, including major markets such as China, the United States, Japan, Europe, South Korea and Australia. The company provides customers with support services for the development, production and CMC declaration of peptides that meet the regulatory requirements of major global markets.
As of January 1, 2023, the company's peptide project pipeline includes 249 CDMO projects and six CMO projects. The company also obtained 72 CDMO projects and 7 CMO projects in 2023. Furthermore, 8,728 CRO projects have been completed throughout 2023. The company is strategically focused on pipeline construction in the glucagon-like peptide 1 (GLP-1) field. As of the last practical date, the company had nine GLP-1 drug development projects with seven customers developing oral and/or injectable GLP-1 products.
In addition to peptides, the company has also developed a diversified project pipeline focusing on other classes of TIDES drugs. For example, expertise has been developed to synthesize complex peptide nucleic acid new chemical entities (NCEs), and a one-stop binding platform has been established. It has the ability to produce milligram to kg grade polypeptides and oligonucleotide binding products, and can meet various qualification requirements. The company's PeptiConjugate and PeptiConjugate LinkTech platforms are dedicated to polypeptide-oligonucleotide conjugated drugs (POC), peptide-conjugated drugs (PDC) and radionuclide conjugated drugs (RDC) projects, which can enable the synthesis, development and production of customized combined products. As of December 31, 2023, the company has successfully synthesized approximately 1,800 molecules through these two platforms.
Ted Pharma's project pipeline also includes various projects related to generic peptide API products for indications such as diabetes, gastrointestinal diseases, and tumors. In addition to simeglutide, the company has also submitted a Drug Master File (DMF) or obtained regulatory approval for several other major generic products. The company also has other major imitation polypeptide products under development, including tiverpotide, diaflavrin, triprorelin dihydroxynaphthalate, teduglutide, etc., to meet more diverse customer needs.
The table below shows details of ongoing projects and new projects during Ted Pharma's track record.
On the financial side, the company achieved revenue of approximately RMB 282 million, RMB 351 million and RMB 337 million in 2021, 2022 and 2023, respectively. Profits during the same period were RMB 80.278 million, RMB 53.98 million, and RMB 48.905 million respectively.
